{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T03:25:27Z","timestamp":1783049127898,"version":"3.54.6"},"reference-count":175,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T00:00:00Z","timestamp":1546905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s12253-018-00569-x","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T00:35:04Z","timestamp":1546994104000},"page":"63-78","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":165,"title":["Hormone Replacement Therapy in Cancer Survivors \u2013 Review of the Literature"],"prefix":"10.1007","volume":"26","author":[{"given":"Tam\u00e1s","family":"Deli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nika","family":"Orosz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Jakab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,8]]},"reference":[{"key":"569_CR1","doi-asserted-by":"crossref","unstructured":"Baber RJ, Panay N, Fenton A, Apr, IMS Writing Group (2016) IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric(2):109\u2013150","DOI":"10.3109\/13697137.2015.1129166"},{"issue":"8","key":"569_CR2","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jamainternmed.2016.2761","volume":"176","author":"MA Lumsden","year":"2016","unstructured":"Lumsden MA, Davies M, Sarri G, Guideline Development Group for Menopause: Diagnosis and Management (NICE Clinical Guideline No. 23) (2016) Diagnosis and Management of Menopause: The National Institute of Health and Care Excellence (NICE) Guideline. JAMA Intern Med 176(8):1205\u20131206","journal-title":"JAMA Intern Med"},{"key":"569_CR3","doi-asserted-by":"crossref","unstructured":"ACOG Practice Bulletin No. 141: management of menopausal symptoms. (2014) Obstet Gynecol. 123(1):202-16.","DOI":"10.1097\/01.AOG.0000441353.20693.78"},{"issue":"4","key":"569_CR4","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/01.ede.0000165392.35273.d4","volume":"16","author":"ME Ossewaarde","year":"2005","unstructured":"Ossewaarde ME, Bots ML, Verbeek AL, Peeters PH, van der Graaf Y, Grobbee DE, van der Schouw YT (2005) Age at menopause, cause-specific mortality and total life expectancy. Epidemiology 16(4):556\u2013562","journal-title":"Epidemiology"},{"issue":"1-2","key":"569_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.mce.2014.02.002","volume":"389","author":"ER Prossnitz","year":"2014","unstructured":"Prossnitz ER, Barton M (2014) Estrogen biology: new insights into GPER function and clinical opportunities. Mol Cell Endocrinol 389(1-2):71\u201383","journal-title":"Mol Cell Endocrinol"},{"key":"569_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jsbmb.2015.06.014","volume":"153","author":"ER Prossnitz","year":"2015","unstructured":"Prossnitz ER, Hathaway HJ (2015) What have we learned about GPER function in physiology and disease from knockout mice? J Steroid Biochem Mol Biol 153:114\u2013126","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"569_CR7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s12672-013-0140-3","volume":"4","author":"R Yamaga","year":"2013","unstructured":"Yamaga R, Ikeda K, Horie-Inoue K, Ouchi Y, Suzuki Y, Inoue S (2013) RNA sequencing of MCF-7 breast cancer cells identifies novel estrogen-responsive genes with functional estrogen receptor-binding sites in the vicinity of their transcription start sites. Horm Cancer 4(4):222\u2013232","journal-title":"Horm Cancer"},{"issue":"6","key":"569_CR8","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1210\/me.2003-0441","volume":"18","author":"V Bourdeau","year":"2004","unstructured":"Bourdeau V, Desch\u00eanes J, M\u00e9tivier R, Nagai Y, Nguyen D, Bretschneider N, Gannon F, White JH, Mader S (2004) Genome-wide identification of high-affinity estrogen response elements in human and mouse. Mol Endocrinol 18(6):1411\u20131427","journal-title":"Mol Endocrinol"},{"issue":"22","key":"569_CR9","doi-asserted-by":"publisher","first-page":"21491","DOI":"10.1074\/jbc.M409176200","volume":"280","author":"S1 Kamalakaran","year":"2005","unstructured":"Kamalakaran S1, Radhakrishnan SK, Beck WT (2005) Identification of estrogen-responsive genes using a genome-wide analysis of promoter elements for transcription factor binding sites. J Biol Chem 280(22):21491\u201321497","journal-title":"J Biol Chem"},{"key":"569_CR10","unstructured":"Sotoca AM, Vervoort J, Rietjens I MCM, Gustafsson JA. (2012) Human ER\u03b1 and ER\u03b2 Splice Variants: Understanding Their Domain Structure in Relation to Their Biological Roles in Breast Cancer Cell Proliferation. Biochemistry, Prof. Deniz Ekinci (Ed.), ISBN: 978-953-51-0076-8, InTech."},{"key":"569_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jsbmb.2016.01.008","volume":"158","author":"Z Xu","year":"2016","unstructured":"Xu Z, Liu J, Gu L, Ma X, Huang B, Pan X (2016) Research progress on the reproductive and non-reproductive endocrine tumors by estrogen-related receptors. J Steroid Biochem Mol Biol 158:22\u201330","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"11","key":"569_CR12","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/s41419-018-1077-9","volume":"9","author":"M Li","year":"2018","unstructured":"Li M, Chai HF, Peng F, Meng YT, Zhang LZ, Zhang L, Zou H, Liang QL, Li MM, Mao KG, Sun DX, Tong MY, Deng ZQ, Hou ZJ, Zhao Y, Li J, Wang XC, Lv SS, Zhang QQ, Yu X, Lam EW, Liu Q, Cui XN, Xu J (2018) Estrogen receptor \u03b2 upregulated by lncRNA-H19 to promote cancer stem-like properties in papillary thyroid carcinoma. Cell Death Dis 9(11):1120","journal-title":"Cell Death Dis"},{"issue":"1","key":"569_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.surg.2017.04.031","volume":"163","author":"GA Rubio","year":"2018","unstructured":"Rubio GA, Catanuto P, Glassberg MK, Lew JI, Elliot SJ (2018) Estrogen receptor subtype expression and regulation is altered in papillary thyroid cancer after menopause. Surgery 163(1):143\u2013149","journal-title":"Surgery"},{"key":"569_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.abb.2017.09.002","volume":"633","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Wei F, Zhang J, Hao L, Jiang J, Dang L, Mei D, Fan S, Yu Y, Jiang L (2017) Bisphenol A and estrogen induce proliferation of human thyroid tumor cells via an estrogen-receptor-dependent pathway. Arch Biochem Biophys 633:29\u201339","journal-title":"Arch Biochem Biophys"},{"key":"569_CR15","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2017.748","volume":"11","author":"MMS Eldien","year":"2017","unstructured":"Eldien MMS, Abdou AG, Rageh T, Abdelrazek E, Elkholy E (2017) Immunohistochemical expression of ER-\u03b1 and PR in papillary thyroid carcinoma. Ecancermedicalscience 11:748. \nhttps:\/\/doi.org\/10.3332\/ecancer.2017.748","journal-title":"Ecancermedicalscience"},{"issue":"5","key":"569_CR16","doi-asserted-by":"publisher","first-page":"8522","DOI":"10.18632\/oncotarget.14338","volume":"8","author":"M Pierdominici","year":"2017","unstructured":"Pierdominici M, Maselli A, Locatelli SL, Ciarlo L, Careddu G, Patrizio M, Ascione B, Tinari A, Carlo-Stella C, Malorni W, Matarrese P, Ortona E (2017) Estrogen receptor \u03b2 ligation inhibits Hodgkin lymphoma growth by inducing autophagy. Oncotarget 8(5):8522\u20138535","journal-title":"Oncotarget"},{"issue":"3-4","key":"569_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3109\/10428190009065836","volume":"39","author":"DM1 Maia","year":"2000","unstructured":"Maia DM1, Sciarrotta J, Abendroth K, Blatt J (2000) Sex steroid receptors in Hodgkin's disease. Leuk Lymphoma 39(3-4):365\u2013371","journal-title":"Leuk Lymphoma"},{"issue":"4B","key":"569_CR18","first-page":"857","volume":"7","author":"E1 Teske","year":"1987","unstructured":"Teske E1, Besselink CM, Blankenstein MA, Rutteman GR, Misdorp W (1987) The occurrence of estrogen and progestin receptors and anti-estrogen binding sites (AEBS) in canine non-Hodgkin's lymphomas. Anticancer Res 7(4B):857\u2013860","journal-title":"Anticancer Res"},{"issue":"3","key":"569_CR19","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1080\/10428194.2016.1213828","volume":"58","author":"EE Ladikou","year":"2017","unstructured":"Ladikou EE, Kassi E (2017) The emerging role of estrogen in B cell malignancies. Leuk Lymphoma 58(3):528\u2013539","journal-title":"Leuk Lymphoma"},{"issue":"1-2","key":"569_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.mce.2013.05.016","volume":"375","author":"K Yakimchuk","year":"2013","unstructured":"Yakimchuk K, Jondal M, Okret S (2013) Estrogen receptor \u03b1 and \u03b2 in the normal immune system and in lymphoid malignancies. Mol Cell Endocrinol 375(1-2):121\u2013129","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"569_CR21","doi-asserted-by":"publisher","first-page":"308","DOI":"10.4103\/JLP.JLP_158_16","volume":"9","author":"M Mukhopadhyay","year":"2017","unstructured":"Mukhopadhyay M, Das C, Kumari M, Sen A, Mukhopadhyay B, Mukhopadhyay B (2017) Spectrum of meningioma with special reference to prognostic utility of ER,PR and Ki67 expression. J Lab Physicians 9(4):308\u2013313","journal-title":"J Lab Physicians"},{"issue":"1","key":"569_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3171\/jns.1997.86.1.0113","volume":"86","author":"DW Hsu","year":"1997","unstructured":"Hsu DW, Efird JT, Hedley-Whyte ET (1997) Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 86(1):113\u2013120","journal-title":"J Neurosurg"},{"key":"569_CR23","doi-asserted-by":"publisher","first-page":"e918","DOI":"10.1016\/j.wneu.2018.07.100","volume":"118","author":"Y Kuroi","year":"2018","unstructured":"Kuroi Y, Matsumoto K, Shibuya M, Kasuya H (2018) Progesterone Receptor Is Responsible for Benign Biology of Skull Base Meningioma. World Neurosurg 118:e918\u2013e924","journal-title":"World Neurosurg"},{"issue":"4","key":"569_CR24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s10143-004-0340-y","volume":"27","author":"S Wolfsberger","year":"2004","unstructured":"Wolfsberger S, Doostkam S, Boecher-Schwarz HG, Roessler K, van Trotsenburg M, Hainfellner JA, Knosp E (2004) Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature. Neurosurg Rev 27(4):238\u2013245","journal-title":"Neurosurg Rev"},{"issue":"5","key":"569_CR25","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1007\/s13277-014-2954-1","volume":"36","author":"M Liu","year":"2015","unstructured":"Liu M, Zhang K, Zhao Y, Guo Q, Guo D, Zhang J (2015) Evidence for involvement of steroid receptors and coactivators in neuroepithelial and meningothelial tumors. Tumour Biol 36(5):3251\u20133261","journal-title":"Tumour Biol"},{"issue":"2","key":"569_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1677\/joe.0.1510175","volume":"151","author":"ML Jaffrain-Rea","year":"1996","unstructured":"Jaffrain-Rea ML, Petrangeli E, Ortolani F, Fraioli B, Lise A, Esposito V, Spagnoli LG, Tamburrano G, Frati L, Gulino A (1996) Cellular receptors for sex steroids in human pituitary adenomas. J Endocrinol 151(2):175\u2013184","journal-title":"J Endocrinol"},{"issue":"1","key":"569_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000217826","volume":"14","author":"B Caronti","year":"1993","unstructured":"Caronti B, Palladini G, Bevilacqua MG, Petrangeli E, Fraioli B, Cantore G, Tamburrano G, Carapella CM, Jaffrain-Rea ML (1993) Effects of 17 beta-estradiol, progesterone and tamoxifen on in vitro proliferation of human pituitary adenomas: correlation with specific cellular receptors. Tumour Biol 14(1):59\u201368","journal-title":"Tumour Biol"},{"key":"569_CR28","doi-asserted-by":"crossref","unstructured":"Natale CA, Li J, Zhang J, Dahal A, Dentchev T, Stanger BZ, Ridky TW. (2018) Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade. Elife. 7. pii: e31770.","DOI":"10.7554\/eLife.31770"},{"issue":"3","key":"569_CR29","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1002\/jcb.26498","volume":"119","author":"W Tian","year":"2018","unstructured":"Tian W, Pang W, Ge Y, He X, Wang D, Li X, Hou H, Zhou D, Feng S, Chen Z, Yang Y (2018) Hepatocyte-generated 27-hydroxycholesterol promotes the growth of melanoma by activation of estrogen receptor alpha. J Cell Biochem 119(3):2929\u20132938","journal-title":"J Cell Biochem"},{"issue":"3","key":"569_CR30","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1684\/ejd.2017.3019","volume":"27","author":"E Dika","year":"2017","unstructured":"Dika E, Fanti PA, Vaccari S, Capizzi E, Degiovanni A, Gobbi A, Piraccini BM, Ribero S, Baraldi C, Ravaioli GM, Fiorentino M, Patrizi A (2017) Oestrogen and progesterone receptors in melanoma and nevi: an immunohistochemical study. Eur J Dermatol 27(3):254\u2013259","journal-title":"Eur J Dermatol"},{"issue":"2","key":"569_CR31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00417-013-2523-0","volume":"252","author":"L Bredow","year":"2014","unstructured":"Bredow L, St\u00fctzel L, B\u00f6hringer D, Gundlach E, Reinhard T, Auw-Haedrich C (2014) Progesterone and estrogen receptors in conjunctival melanoma and nevi. Graefes Arch Clin Exp Ophthalmol 252(2):359\u2013365","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"569_CR32","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3389\/fendo.2018.00470","volume":"9","author":"S Hiramitsu","year":"2018","unstructured":"Hiramitsu S, Ishikawa T, Lee WR, Khan T, Crumbley C, Khwaja N, Zamanian F, Asghari A, Sen M, Zhang Y, Hawse JR, Minna JD, Umetani M (2018) Estrogen Receptor Beta-Mediated Modulation of Lung Cancer Cell Proliferation by 27-Hydroxycholesterol. Front Endocrinol (Lausanne) 9:470","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"569_CR33","first-page":"2382","volume":"16","author":"X Ding","year":"2018","unstructured":"Ding X, Li L, Tang C, Meng C, Xu W, Wei X, Guo Z, Zhang T, Fu Y, Zhang L, Wang X, Lin L, Liang J (2018) Cytoplasmic expression of estrogen receptor \u03b2 may predict poor outcome of EGFR-TKI therapy in metastatic lung adenocarcinoma. Oncol Lett 16(2):2382\u20132390","journal-title":"Oncol Lett"},{"issue":"3","key":"569_CR34","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s12253-017-0268-5","volume":"24","author":"PR Stevanato Filho","year":"2018","unstructured":"Stevanato Filho PR, Aguiar J\u00fanior S, Begnami MD, Ferreira FO, Nakagawa WT, Spencer RMSB, Bezerra TS, Boggiss PE, Lopes A (2018) Estrogen Receptor \u03b2 as a Prognostic Marker of Tumor Progression in Colorectal Cancer with Familial Adenomatous Polyposis and Sporadic Polyps. Pathol Oncol Res 24(3):533\u2013540","journal-title":"Pathol Oncol Res"},{"issue":"16","key":"569_CR35","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1111\/febs.13798","volume":"283","author":"D Liu","year":"2016","unstructured":"Liu D (2016) Gene signatures of estrogen and progesterone receptor pathways predict the prognosis of colorectal cancer. FEBS J 283(16):3115\u20133133","journal-title":"FEBS J"},{"issue":"2","key":"569_CR36","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.canlet.2016.05.019","volume":"378","author":"CT Kuo","year":"2016","unstructured":"Kuo CT, Lee WS (2016) Progesterone receptor activation is required for folic acid-induced anti-proliferation in colorectal cancer cell lines. Cancer Lett 378(2):104\u2013110","journal-title":"Cancer Lett"},{"key":"569_CR37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ijsu.2018.03.027","volume":"53","author":"H Ge","year":"2018","unstructured":"Ge H, Yan Y, Tian F, Wu D, Huang Y (2018) Prognostic value of estrogen receptor \u03b1 and estrogen receptor \u03b2 in gastric cancer based on a meta-analysis and The Cancer Genome Atlas (TCGA) datasets. Int J Surg 53:24\u201331","journal-title":"Int J Surg"},{"issue":"37","key":"569_CR38","doi-asserted-by":"publisher","first-page":"6802","DOI":"10.3748\/wjg.v23.i37.6802","volume":"23","author":"JK Iyer","year":"2017","unstructured":"Iyer JK, Kalra M, Kaul A, Payton ME, Kaul R (2017) Estrogen receptor expression in chronic hepatitis C and hepatocellular carcinoma pathogenesis. World J Gastroenterol 23(37):6802\u20136816","journal-title":"World J Gastroenterol"},{"key":"569_CR39","doi-asserted-by":"crossref","unstructured":"Tsai HW, Ho CL, Cheng SW, Lin YJ, Chen CC, Cheng PN, Yen CJ, Chang TT, Chiang PM, Chan SH, Ho CH, Chen SH, Wang YW, Chow NH, Lin JC. (2018) Progesterone receptor membrane component 1 as a potential prognostic biomarker for hepatocellular carcinoma. World J Gastroenterol 2018 Mar 14;24(10):1152-1166.","DOI":"10.3748\/wjg.v24.i10.1152"},{"issue":"9","key":"569_CR40","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.tem.2017.05.006","volume":"28","author":"D Garg","year":"2017","unstructured":"Garg D, Man Ng SS, Baig KM, Driggers P, Segars J (2017) Progesterone-Mediated Non-Classical Signaling. Trends Endocrinol Metab 28(9):656\u2013668","journal-title":"Trends Endocrinol Metab"},{"issue":"2-4","key":"569_CR41","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1387\/ijdb.140069mw","volume":"58","author":"M Wetendorf","year":"2014","unstructured":"Wetendorf M, DeMayo FJ (2014) Progesterone receptor signaling in the initiation of pregnancy and preservation of a healthy uterus. Int J Dev Biol 58(2-4):95\u2013106","journal-title":"Int J Dev Biol"},{"key":"569_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fendo.2012.00007","volume":"3","author":"SK Mani","year":"2012","unstructured":"Mani SK, Oyola MG (2012) Progesterone signaling mechanisms in brain and behavior. Front Endocrinol (Lausanne) 3:7","journal-title":"Front Endocrinol (Lausanne)"},{"key":"569_CR43","unstructured":"American Cancer Society. (2016) Cancer Facts & Figures 2016. Atlanta: American Cancer Society \nhttps:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2016\/cancer-facts-and-figures-2016.pdf"},{"issue":"4","key":"569_CR44","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1177\/107327481201900408","volume":"19","author":"V Murthy","year":"2012","unstructured":"Murthy V, Chamberlain RS (2012) Menopausal symptoms in young survivors of breast cancer: a growing problem without an ideal solution. Cancer Control 19(4):317\u2013329","journal-title":"Cancer Control"},{"issue":"7","key":"569_CR45","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1001\/jama.1994.03520070060039","volume":"272","author":"MA Cobleigh","year":"1994","unstructured":"Cobleigh MA, Berris RF, Bush T (1994) Estrogen replacement therapy in breast cancer survivors. A time for change. JAMA 272(7):540\u2013545","journal-title":"JAMA"},{"issue":"5","key":"569_CR46","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1200\/JCO.1999.17.5.1482","volume":"17","author":"R Vassilopoulou-Sellin","year":"1999","unstructured":"Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, Klein MJ, McNeese M, Singletary SE, Theriault RL (1999) Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. J Clin Oncol 17(5):1482\u20131487","journal-title":"J Clin Oncol"},{"issue":"1","key":"569_CR47","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1006\/gyno.1997.4621","volume":"65","author":"R Vassilopoulou-Sellin","year":"1997","unstructured":"Vassilopoulou-Sellin R, Theriault R, Klein MJ (1997) Estrogen Replacement Therapy in Women with Prior Diagnosis and Treatment for Breast Cancer. Gynecol Oncol 65(1):89\u201393","journal-title":"Gynecol Oncol"},{"issue":"10","key":"569_CR48","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/jnci\/93.10.754","volume":"93","author":"ES O'Meara","year":"2001","unstructured":"O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS (2001) Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 93(10):754\u2013762","journal-title":"J Natl Cancer Inst"},{"issue":"9407","key":"569_CR49","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0140-6736(04)15493-7","volume":"363","author":"Holmberg L, Anderson H, HABITS steering and data monitoring committees","year":"2004","unstructured":"Holmberg L, Anderson H, HABITS steering and data monitoring committees (2004) HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped. Lancet 363(9407):453\u2013455","journal-title":"Lancet"},{"issue":"4","key":"569_CR50","first-page":"322","volume":"6","author":"M Lupo","year":"2015","unstructured":"Lupo M, Dains JE, Madsen LT (2015) Hormone Replacement Therapy: An Increased Risk of Recurrence and Mortality for Breast Cancer Patients? J Adv Pract Oncol 6(4):322\u2013330","journal-title":"J Adv Pract Oncol"},{"issue":"28","key":"569_CR51","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1200\/JCO.2007.10.6815","volume":"25","author":"A Brewster","year":"2007","unstructured":"Brewster A, Do KA, Thompson PA, Hahn KA, Sahin AA, Cao Y, Stewart MM, Murray JL, Hortobagyi GN, Bondy ML (2007) Relationship between epidemiologic risk factors and breast cancer recurrence. J Clin Oncol 25(28):4438\u20134444","journal-title":"J Clin Oncol"},{"issue":"7","key":"569_CR52","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/jnci\/djn058","volume":"100","author":"L Holmberg","year":"2008","unstructured":"Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, Jassem J, Dobaczewska D, Fjosne HE, Peralta O, Arriagada R, Holmqvist M, Maenpaa J, HABITS Study Group (2008) Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 100(7):475\u2013482","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"569_CR53","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejca.2012.07.003","volume":"49","author":"M Fahl\u00e9n","year":"2013","unstructured":"Fahl\u00e9n M, Fornander T, Johansson H, Johansson U, Rutqvist LE, Wilking N, von Schoultz E (2013) Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer 49(1):52\u201359","journal-title":"Eur J Cancer"},{"issue":"7","key":"569_CR54","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1056\/NEJMoa0800743","volume":"359","author":"SR Cummings","year":"2008","unstructured":"Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, Johnson S, Zanchetta J, Grobbee DE, Seifert W, Eastell R, Trial Investigators LIFT (2008) The Effects of Tibolone in Older Postmenopausal Women. N Engl J Med 359(7):697\u2013708","journal-title":"N Engl J Med"},{"issue":"2","key":"569_CR55","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S1470-2045(08)70341-3","volume":"10","author":"P Kenemans","year":"2009","unstructured":"Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os S, Beckmann MW, LIBERATE Study Group (2009) Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 10(2):135\u2013146","journal-title":"Lancet Oncol"},{"issue":"1","key":"569_CR56","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1186\/bcr3097","volume":"14","author":"NJ Bundred","year":"2012","unstructured":"Bundred NJ, Kenemans P, Yip CH, Beckmann MW, Foidart JM, Sismondi P, Schoultz B, Vassilopoulou-Sellin R, Galta RE, Lieshout EV, Mol-Arts M, Planellas J, Kubista E (2012) Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy. Breast Cancer Res 14(1):R13","journal-title":"Breast Cancer Res"},{"issue":"4","key":"569_CR57","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.maturitas.2011.09.003","volume":"70","author":"P1 Sismondi","year":"2011","unstructured":"Sismondi P1, Kimmig R, Kubista E, Biglia N, Egberts J, Mulder R, Planellas J, Moggio G, Mol-Arts M, Kenemans P (2011) Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial. Maturitas 70(4):365\u2013372","journal-title":"Maturitas"},{"issue":"4","key":"569_CR58","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1524-4741.2011.01089.x","volume":"17","author":"S1 Pruthi","year":"2011","unstructured":"Pruthi S1, Simon JA, Early AP (2011) Current overview of the management of urogenital atrophy in women with breast cancer. Breast J 17(4):403\u2013408","journal-title":"Breast J"},{"issue":"7","key":"569_CR59","doi-asserted-by":"publisher","first-page":"347","DOI":"10.5694\/j.1326-5377.2002.tb04835.x","volume":"177","author":"EM1 Durna","year":"2002","unstructured":"Durna EM1, Wren BG, Heller GZ, Leader LR, Sjoblom P, Eden JA (2002) Hormone replacement therapy after a diagnosis of breast cancer: Cancer recurrence and mortality. Med J Aust 177(7):347\u2013351","journal-title":"Med J Aust"},{"key":"569_CR60","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejca.2012.07.003","volume":"49","author":"M Fahlen","year":"2013","unstructured":"Fahlen M, Fornander T, Johansson H, Johansson U, Rutqvist LE, Wilking M, von Schoultz E (2013) Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer 49:52\u201359","journal-title":"Eur J Cancer"},{"issue":"4","key":"569_CR61","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/01.GME.0000061806.76067.E9","volume":"10","author":"DA Decker","year":"2003","unstructured":"Decker DA, Pettinga JE, VanderVelde N, Huang RR, Kestin L, Burdakin JH (2003) Estrogen replacement therapy in breast cancer survivors: A matched-controlled series. Menopause 10(4):277\u2013285","journal-title":"Menopause"},{"issue":"6","key":"569_CR62","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/00000421-200012000-00001","volume":"23","author":"PJ DiSaia","year":"2000","unstructured":"DiSaia PJ, Brewster WR, Ziogas A, Anton-Culver H (2000) Breast cancer survival and hormone replacement therapy: A cohort analysis. Am J Clin Oncol 23(6):541\u2013545","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"569_CR63","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2217\/WHE.12.41","volume":"8","author":"A Finch","year":"2012","unstructured":"Finch A, Evans G, Narod SA (2012) BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Women's Health (Lond) 8(5):543\u2013555","journal-title":"Women's Health (Lond)"},{"issue":"8","key":"569_CR64","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1001\/jamaoncol.2018.0211","volume":"4","author":"J Kotsopoulos","year":"2018","unstructured":"Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A, Singer CF, Foulkes WD, Jacobson MR, Sun P, Lubinski J, Narod SA, Hereditary Breast Cancer Clinical Study Group (2018) Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. JAMA Oncol 4(8):1059\u20131065","journal-title":"JAMA Oncol"},{"issue":"6","key":"569_CR65","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<1013::AID-CNCR17>3.0.CO;2-1","volume":"86","author":"F1 Guidozzi","year":"1999","unstructured":"Guidozzi F1, Daponte A (1999) Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial. Cancer 86(6):1013\u20131018","journal-title":"Cancer"},{"issue":"12","key":"569_CR66","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1002\/ijc.22218","volume":"119","author":"C1 Mascarenhas","year":"2006","unstructured":"Mascarenhas C1, Lambe M, Bellocco R, Bergfeldt K, Riman T, Persson I, Weiderpass E (2006) Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int J Cancer 119(12):2907\u20132915","journal-title":"Int J Cancer"},{"key":"569_CR67","doi-asserted-by":"crossref","unstructured":"Eeles RA, Morden JP, Gore M, Mansi J, Glees J, Wenczl M, Williams C, Kitchener H, Osborne R, Guthrie D, Harper P, Bliss JM. (2015) Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial. J Clin Oncol 2015 Dec 10;33(35):4138-4144.","DOI":"10.1200\/JCO.2015.60.9719"},{"issue":"3","key":"569_CR68","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/GME.0000000000000508","volume":"23","author":"V Pergialiotis","year":"2016","unstructured":"Pergialiotis V, Pitsouni E, Prodromidou A, Frountzas M, Perrea DN, Vlachos GD (2016) Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis. Menopause 23(3):335\u2013342","journal-title":"Menopause"},{"issue":"6771","key":"569_CR69","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1136\/bmj.302.6771.259","volume":"302","author":"RA Eeles","year":"1991","unstructured":"Eeles RA, Tan S, Wiltshaw E, Fryatt I, A\u2019Hern RP, Shepherd JH, Harmer CL, Blake RP, Chilvers CE (1991) Hormone replacement therapy and survival after surgery for ovarian. BMJ 302(6771):259\u2013262","journal-title":"BMJ"},{"issue":"1","key":"569_CR70","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/00042192-200101000-00012","volume":"8","author":"M Ursic-Vrscaj","year":"2001","unstructured":"Ursic-Vrscaj M, Bebar S, Zakelj MP (2001) Hormone replacement therapy after invasive ovarian serous cystadeno carcinoma treatment: the effect on survival. Menopause 8(1):70\u201375","journal-title":"Menopause"},{"key":"569_CR71","doi-asserted-by":"crossref","unstructured":"Be\u0161evi\u0107 J, Gunter MJ, Fortner RT, Tsilidis KS, Weiderpass E, Onland-Moret NE, Dossus L, Tj\u00f8nneland A, Hansen L, Overvad K, Mesrine S, Baglietto L, Clavel-Chapelon F, Kaaks R, Aleksandrova K, Boeing H, Trichopoulou A, Lagiou P, Bamia C, Masala G, Agnoli C, Tumino R, Ricceri F, Panico S, HB (as) Bueno-de-Mesquita, Peeters PH, Jareid M, Quir\u00f3s JR, Duell EJ, S\u00e1nchez MJ, Larra\u00f1aga N, Chirlaque MD, Barricarte A, Dias JA, Sonestedt E, Idahl A, Lundin E, Wareham NJ, Khaw KT, Travis RC, Rinaldi S, Romieu I, Riboli E, Merritt MA. (2015) Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study. Br J Cancer 113(11):1622-1631.","DOI":"10.1038\/bjc.2015.377"},{"issue":"3","key":"569_CR72","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/GME.0000000000000508","volume":"23","author":"V Pergialiotis","year":"2016","unstructured":"Pergialiotis V, Pitsouni E, Prodromidou A, Frountzas M, Perrea DN, Vlachos GD (2016) Hormone therapy for ovarian cancer survivors: systematic reviewand meta-analysis. Menopause 23(3):335\u2013342","journal-title":"Menopause"},{"key":"569_CR73","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.maturitas.2016.07.018","volume":"92","author":"CL Kuhle","year":"2016","unstructured":"Kuhle CL, Kapoor E, Sood R, Thielen JM, Jatoi A, Faubion SS (2016) Menopausal hormone therapy in cancer survivors: A narrative review of the literature. Maturitas 92:86\u201396","journal-title":"Maturitas"},{"issue":"3","key":"569_CR74","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.maturitas.2015.07.006","volume":"82","author":"N Biglia","year":"2015","unstructured":"Biglia N, Bounous VE, Sgro LG, D'Alonzo M, Gallo M (2015) Treatment of climacteric symptoms in survivors of gynaecological cancer. Maturitas 82(3):296\u2013298","journal-title":"Maturitas"},{"issue":"2","key":"569_CR75","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ygyno.2017.06.013","volume":"146","author":"MG Carmen Del","year":"2017","unstructured":"Del Carmen MG, Rice LW (2017) Management of menopausal symptoms in women with gynecologic cancers. Gynecol Oncol 146(2):427\u2013435","journal-title":"Gynecol Oncol"},{"key":"569_CR76","doi-asserted-by":"crossref","unstructured":"Singh P, Oehler MK. (2010) Hormone replacement after gynaecological cancer. Maturitas 2010 Mar;65(3):190-197.","DOI":"10.1016\/j.maturitas.2009.11.017"},{"issue":"3","key":"569_CR77","first-page":"326","volume":"67","author":"WT Creasman","year":"1986","unstructured":"Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL (1986) Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 67(3):326\u2013330","journal-title":"Obstet Gynecol"},{"issue":"2","key":"569_CR78","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0090-8258(90)90171-G","volume":"36","author":"RB Lee","year":"1990","unstructured":"Lee RB, Burke TW, Park RC (1990) Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 36(2):189\u2013191","journal-title":"Gynecol Oncol"},{"issue":"5","key":"569_CR79","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0002-9378(96)70027-3","volume":"175","author":"JA Chapman","year":"1996","unstructured":"Chapman JA, DiSaia PJ, Osann K, Roth PD, Gillotte DL, Berman ML (1996) Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 175(5):1195\u20131200","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"569_CR80","first-page":"555","volume":"97","author":"KA Suriano","year":"2001","unstructured":"Suriano KA, McHale M, McLaren CE, Li KT, Re A, DiSaia PJ (2001) Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol 97(4):555\u2013560","journal-title":"Obstet Gynecol"},{"issue":"2","key":"569_CR81","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/j.1525-1438.2006.00526.x","volume":"16","author":"A Ayhan","year":"2006","unstructured":"Ayhan A, Taskiran C, Simsek S, Sever A (2006) Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors? Int J Gynecol Cancer 16(2):805\u2013808","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"569_CR82","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2005.02.8464","volume":"24","author":"RR Barakat","year":"2006","unstructured":"Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS, Gynecologic Oncology Group Study (2006) Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology group study. J Clin Oncol 24(4):587\u2013592","journal-title":"J Clin Oncol"},{"issue":"9","key":"569_CR83","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.ejca.2014.03.006","volume":"50","author":"SH Shim","year":"2014","unstructured":"Shim SH, Lee SJ, Kim SN (2014) Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. Eur J Cancer 50(9):1628\u20131637","journal-title":"Eur J Cancer"},{"issue":"3","key":"569_CR84","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ygyno.2005.11.010","volume":"101","author":"D Pink","year":"2006","unstructured":"Pink D, Lindner T, Mrozek A, Kretzschmar A, Thuss-Patience PC, D\u00f6rken B, Reichardt P (2006) Harm or benefit of hormone replacement in metastatic low-grade endometrial stromal sarcoma: single centre experience with 10 cases and review of literature. Gynecol Oncol 101(3):464\u2013469","journal-title":"Gynecol Oncol"},{"issue":"4","key":"569_CR85","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/00129039-200412000-00008","volume":"12","author":"TW Kelley","year":"2004","unstructured":"Kelley TW, Borden EC, Goldblum JR (2004) Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study. Appl Immunohistochem Mol Morphol 12(4):338\u2013341","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"4","key":"569_CR86","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/cncr.23245","volume":"112","author":"DS Kapp","year":"2008","unstructured":"Kapp DS, Shin JY, Chan JK (2008) Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer 112(4):820\u2013830","journal-title":"Cancer"},{"issue":"6","key":"569_CR87","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3109\/13697137.2013.806471","volume":"16","author":"F Guidozzi","year":"2013","unstructured":"Guidozzi F (2013) Estrogen therapy in gynecological cancer survivors. Climacteric 16(6):611\u2013617","journal-title":"Climacteric"},{"key":"569_CR88","doi-asserted-by":"crossref","unstructured":"Ploch E. (1987) Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol 1987 Feb;26(2):169-177.","DOI":"10.1016\/0090-8258(87)90270-8"},{"issue":"12","key":"569_CR89","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1002\/ijc.23446","volume":"122","author":"BS1 Madsen","year":"2008","unstructured":"Madsen BS1, Jensen HL, van den Brule AJ, Wohlfahrt J, Frisch M (2008) Risk factors for invasive squamous cell carcinoma of the vulva and vagina--population-based case-control study in Denmark. Int J Cancer 122(12):2827\u20132834","journal-title":"Int J Cancer"},{"issue":"11","key":"569_CR90","first-page":"857","volume":"39","author":"KJ Sherman","year":"1994","unstructured":"Sherman KJ, Daling JR, McKnight B, Chu J (1994) Hormonal factors in vulvar cancer. A case\u2013control study. J Reprod Med 39(11):857\u2013861","journal-title":"J Reprod Med"},{"issue":"2","key":"569_CR91","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1080\/01443610500050991","volume":"25","author":"GO Somoye","year":"2005","unstructured":"Somoye GO, Gull S (2005) Adenocarcinoma of the vaginal vault following prolonged unopposed estrogen hormone replacement therapy. J Obstet Gynaecol 25(2):220\u2013221","journal-title":"J Obstet Gynaecol"},{"key":"569_CR92","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/j.1600-065X.2000.imr017502.x","volume":"175","author":"PW Kincade","year":"2000","unstructured":"Kincade PW, Medina KL, Payne KJ, Rossi MI, Tudor KS, Yamashita Y, Kouro T (2000) Early B-lymphocyte precursors and their regulation by sex steroids. Immunol Rev 175:128\u2013137","journal-title":"Immunol Rev"},{"issue":"16","key":"569_CR93","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1016\/j.yexcr.2008.07.015","volume":"314","author":"MA Kauss","year":"2008","unstructured":"Kauss MA, Reiterer G, Bunaciu RP, Yen A (2008) Human myeloblastic leukemiacells (HL-60) express a membrane receptor for estrogen that signals and modulates retinoic acid-induced cell differentiation. Exp Cell Res 314(16):2999\u20133006","journal-title":"Exp Cell Res"},{"issue":"5","key":"569_CR94","first-page":"1077","volume":"5","author":"Q Li","year":"1999","unstructured":"Li Q, Kopecky KJ, Mohan A, Willman CL, Appelbaum FR, Weick JK, Issa JP (1999) Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia. Clin Cancer Res 5(5):1077\u20131084","journal-title":"Clin Cancer Res"},{"issue":"9","key":"569_CR95","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S0145-2126(97)00062-3","volume":"21","author":"A Tavani","year":"1997","unstructured":"Tavani A, Pregnolato A, La Vecchia C, Franceschi S (1997) A case-control study of reproductive factors and risk of lymphomas and myelomas. Leuk Res 21(9):885\u2013888","journal-title":"Leuk Res"},{"issue":"5","key":"569_CR96","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1200\/JCO.2001.19.5.1381","volume":"19","author":"RA Nelson","year":"2001","unstructured":"Nelson RA, Levine AM, Bernstein L (2001) Reproductive factors and risk of intermediate-or high-grade B-cell non-Hodgkin\u2019s lymphoma in women. J Clin Oncol 19(5):1381\u20131387","journal-title":"J Clin Oncol"},{"issue":"6","key":"569_CR97","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1182\/blood.V95.6.2059","volume":"95","author":"KL Medina","year":"2000","unstructured":"Medina KL, Strasser A, Kincade PW (2000) Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors. Blood 95(6):2059\u20132067","journal-title":"Blood"},{"issue":"3","key":"569_CR98","doi-asserted-by":"publisher","first-page":"186","DOI":"10.7326\/0003-4819-127-3-199708010-00002","volume":"127","author":"HA Preti","year":"1997","unstructured":"Preti HA, Cabanillas F, Talpaz M, Tucker SL, Seymour JF, Kurzrock R (1997) Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 127(3):186\u2013194","journal-title":"Ann Intern Med"},{"issue":"6","key":"569_CR99","first-page":"2043","volume":"83","author":"D Cheleuitte","year":"1998","unstructured":"Cheleuitte D, Mizuno S, Glowacki J (1998) In vitro secretion of cytokines by human bone marrow: effects of age and estrogen status. J Clin Endocrinol Metab 83(6):2043\u20132051","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"569_CR100","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1080\/13697137.2017.1309382","volume":"20","author":"X Yang","year":"2017","unstructured":"Yang X, Wang C, He X, Wei J, Wang Y, Li X, Xu LP (2017) Hormone therapy for premature ovarian insufficiency patients with malignant hematologic diseases. Climacteric 20(3):268\u2013273","journal-title":"Climacteric"},{"issue":"2","key":"569_CR101","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/01.gme.0000232032.84788.8c","volume":"14","author":"L Tauchmanov\u00e0","year":"2007","unstructured":"Tauchmanov\u00e0 L, Selleri C, De Rosa G, Sammartino A, Di Carlo C, Musella T, Martorelli C, Lombardi G, Rotoli B, Nappi C, Colao A (2007) Estrogen-progestin therapy in women after stem cell transplant: our experience and literature review. Menopause 14(2):320\u2013330","journal-title":"Menopause"},{"issue":"4","key":"569_CR102","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1017\/S0317167100032960","volume":"24","author":"PM Black","year":"1997","unstructured":"Black PM (1997) Hormones, radiosurgery and virtual reality: new aspects of meningioma management. Can J Neurol Sci 24(4):302\u2013306","journal-title":"Can J Neurol Sci"},{"key":"569_CR103","unstructured":"Carroll RS, Brown M, Zhang J, DiRenzo J, Font De Mora J, McL. Black P. (2000) Expression of a subset of steroid receptor cofactors is associated with progesterone receptor expression in meningiomas. Clin Cancer Res 6:3570\u20133575."},{"issue":"1","key":"569_CR104","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3171\/jns.1997.86.1.0113","volume":"86","author":"DW Hsu","year":"1997","unstructured":"Hsu DW, Efird JT, Hedley-Whyte ET (1997) Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 86(1):113\u2013120","journal-title":"J Neurosurg"},{"issue":"2","key":"569_CR105","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1590\/S0004-282X1998000200005","volume":"56","author":"A Hilbig","year":"1998","unstructured":"Hilbig A, Barbosa-Coutinho LM (1998) Meningiomas and hormonal receptors. Immunohistochemical study in typical and non-typical tumors. Arq Neuropsiquiatr 56(2):193\u2013199","journal-title":"Arq Neuropsiquiatr"},{"issue":"2","key":"569_CR106","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3109\/13697137.2010.533615","volume":"14","author":"A Pines","year":"2011","unstructured":"Pines A (2011) Hormon therapy and brain tumors. Climacteric 14(2):215\u2013216","journal-title":"Climacteric"},{"key":"569_CR107","doi-asserted-by":"crossref","unstructured":"O'Shea T, Crowley RK, Farrell M, MacNally S, Govender P, Feeney J, Gibney J, Sherlock M. (2016) Growth of a progesterone receptor-positive meningioma in a female patient with congenital adrenal hyperplasia. Endocrinol Diabetes Metab Case Rep. 2016 pii: 16-0054.","DOI":"10.1530\/EDM-16-0054"},{"issue":"10","key":"569_CR108","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1002\/ijc.29274","volume":"136","author":"VS Benson","year":"2015","unstructured":"Benson VS, Kirichek O, Beral V, Green J (2015) Menopausal hormone therapy and central nervous system tumor risk: large UK prospective study and meta-analysis. Int J Cancer 136(10):2369\u20132377","journal-title":"Int J Cancer"},{"issue":"12","key":"569_CR109","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083261","volume":"8","author":"ZY Qi","year":"2013","unstructured":"Qi ZY, Shao C, Huang YL, Hui GZ, Zhou YX, Wang Z (2013) Reproductive and exogenous hormone factors in relation to risk of meningioma in women: a meta-analysis. PLoS One 8(12):e83261","journal-title":"PLoS One"},{"issue":"2","key":"569_CR110","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s11060-017-2656-9","volume":"136","author":"TA Harland","year":"2018","unstructured":"Harland TA, Freeman JL, Davern M, McCracken DJ, Celano EC, Lillehei K, Olson JJ, Ormond DR (2018) Progesterone-only contraception is associated with a shorter progression-free survival in premenopausal women with WHO Grade I meningioma. J Neuro-Oncol 136(2):327\u2013333","journal-title":"J Neuro-Oncol"},{"issue":"2-3","key":"569_CR111","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ando.2007.03.008","volume":"68","author":"S Christin-Ma\u00eetre","year":"2007","unstructured":"Christin-Ma\u00eetre S, Delemer B, Touraine P, Young J (2007) Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy. Ann Endocrinol (Paris) 68(2-3):106\u2013112","journal-title":"Ann Endocrinol (Paris)"},{"issue":"5","key":"569_CR112","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/13697130902929559","volume":"12","author":"T Sathyapalan","year":"2009","unstructured":"Sathyapalan T, Gonz\u00e1lez S, Atkin SL (2009) Effect of long-term, high-dose estrogen treatment on prolactin levels: a retrospective analysis. Climacteric 12(5):427\u2013430","journal-title":"Climacteric"},{"issue":"7","key":"569_CR113","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00432-017-2387-5","volume":"143","author":"V Giorgi De","year":"2017","unstructured":"De Giorgi V, Gori A, Savarese I, D\u2019Errico A, Scarf\u00ec F, Papi F, Maio V, Covarelli P, Massi D, Gandini S (2017) Role of BMI and hormone therapy in melanoma risk: a case\u2013control study. J Cancer Res Clin Oncol 143(7):1191\u20131197","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"569_CR114","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/sj.bjc.6601595","volume":"90","author":"RM MacKie","year":"2004","unstructured":"MacKie RM, Bray CA (2004) Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma. Br J Cancer 90(4):770\u2013772","journal-title":"Br J Cancer"},{"issue":"9","key":"569_CR115","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1002\/ijc.30878","volume":"141","author":"E Botteri","year":"2017","unstructured":"Botteri E, St\u00f8er NC, Sakshaug S, Graff-Iversen S, Vangen S, Hofvind S, Ursin G, Weiderpass E (2017) Menopausal hormone therapy and risk of melanoma: Do estrogens and progestins have a different role? Int J Cancer 141(9):1763\u20131770","journal-title":"Int J Cancer"},{"key":"569_CR116","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3389\/fendo.2016.00140","volume":"7","author":"M Marzagalli","year":"2016","unstructured":"Marzagalli M, Marelli MM, Casati L, Fontana F, Moretti RM, Limonta P (2016) Estrogen Receptor \u03b2 in Melanoma: From Molecular Insights to Potential Clinical Utility. Front Endocrinol (Lausanne) 7:140","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"569_CR117","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134396","volume":"10","author":"M Marzagalli","year":"2015","unstructured":"Marzagalli M, Casati L, Moretti RM, Montagnani Marelli M, Limonta P (2015) Estrogen receptor beta agonists differentially affect the growth of human melanoma cell lines. PLoS One 10(7):e0134396","journal-title":"PLoS One"},{"issue":"8","key":"569_CR118","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrc3093","volume":"11","author":"C Thomas","year":"2011","unstructured":"Thomas C, Gustafsson JA (2011) The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 11(8):597\u2013608","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"569_CR119","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1586\/era.11.42","volume":"11","author":"V Giorgi de","year":"2011","unstructured":"de Giorgi V, Gori A, Grazzini M, Rossari S, Scarf\u00ec F, Corciova S, Verdelli A, Lotti T, Massi D (2011) Estrogens, estrogen receptors and melanoma. Expert Rev Anticancer Ther 11(5):739\u2013747","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"569_CR120","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/bjd.12056","volume":"168","author":"V Giorgi de","year":"2013","unstructured":"de Giorgi V, Gori A, Gandini S, Papi F, Grazzini M, Rossari S, Simoni A, Maio V, Massi D (2013) Oestrogen receptor beta and melanoma: a comparative study. Br J Dermatol 168(3):513\u2013519","journal-title":"Br J Dermatol"},{"issue":"4","key":"569_CR121","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/sj.bjc.6601595","volume":"90","author":"RM MacKie","year":"2004","unstructured":"MacKie RM, Bray CA (2004) Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma. Br J Cancer 90(4):770\u2013772","journal-title":"Br J Cancer"},{"issue":"8","key":"569_CR122","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.3390\/ijms18081713","volume":"18","author":"LH Hsu","year":"2017","unstructured":"Hsu LH, Chu NM, Kao SH (2017) Estrogen, Estrogen Receptor and Lung Cancer. Int J Mol Sci 18(8):1713","journal-title":"Int J Mol Sci"},{"issue":"2","key":"569_CR123","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.mce.2011.02.018","volume":"340","author":"Y Miki","year":"2011","unstructured":"Miki Y, Abe K, Suzuki S, Suzuki T, Sasano H (2011) Suppression of estrogen actions in human lung cancer. Mol Cell Endocrinol 340(2):168\u2013174","journal-title":"Mol Cell Endocrinol"},{"key":"569_CR124","unstructured":"Chlebowski RT, Anderson GL, Manson JE, Schwartz AG, Wakelee H, Gass M, Rodabough RJ, Johnson KC, Wactawski-Wende J, Kotchen JM, Ockene JK, O'Sullivan MJ, Hubbell FA, Chien JW, Chen C, Stefanick ML. (2010) Lung cancer among postmenopausal women treated with estrogen alone inthe women\u2019s health initiative randomized trial. J Natl Cancer Inst 2010 Sep 22;102(18):1413-1421."},{"issue":"7","key":"569_CR125","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103735","volume":"9","author":"J Clague","year":"2014","unstructured":"Clague J, Reynolds P, Henderson KD, Sullivan-Halley J, Ma H, Lacey JV Jr, Chang S, Delclos GL, Du XL, Forman MR, Bernstein L (2014) Menopausal hormone therapy and lung cancer-specific mortality following diagnosis:the California teachers study. PLoS One 9(7):e103735","journal-title":"PLoS One"},{"issue":"1","key":"569_CR126","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1200\/JCO.2005.02.9827","volume":"24","author":"AK1 Ganti","year":"2016","unstructured":"Ganti AK1, Sahmoun AE, Panwalkar AW, Tendulkar KK, Potti A (2016) Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 24(1):59\u201363","journal-title":"J Clin Oncol"},{"issue":"2","key":"569_CR127","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.mce.2011.02.018","volume":"340","author":"Y Miki","year":"2011","unstructured":"Miki Y, Abe K, Suzuki S, Suzuki T, Sasano H (2011) Suppression of estrogen actions in human lung cancer. Mol Cell Endocrinol 340(2):168\u2013174","journal-title":"Mol Cell Endocrinol"},{"issue":"18","key":"569_CR128","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1056\/NEJMoa054967","volume":"355","author":"J Regula","year":"2006","unstructured":"Regula J, Rupinski M, Kraszewska E, Polkowski M, Pachlewski J, Orlowska J, Nowacki MP, Butruk E (2006) Colonoscopy in colorectal-cancerscreening for detection of advanced neoplasia. N Engl J Med 355(18):1863\u20131872","journal-title":"N Engl J Med"},{"issue":"6","key":"569_CR129","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1111\/j.1572-0241.2007.01779.x","volume":"103","author":"JH Koo","year":"2008","unstructured":"Koo JH, Jalaludin B, Wong SK, Kneebone A, Connor SJ et al (2008) Improved survival in young women with colorectal cancer. Am J Gastroenterol 103(6):1488\u20131495","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"569_CR130","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/bjs.4098","volume":"90","author":"CS McArdle","year":"2003","unstructured":"McArdle CS, McMillan DC, Hole DJ (2003) Male gender adversely affects survival following surgery for colorectal cancer. Br J Surg 90(6):711\u2013715","journal-title":"Br J Surg"},{"key":"569_CR131","doi-asserted-by":"crossref","unstructured":"Murphy N, Strickler HD, Stanczyk FZ, Xue X, Wassertheil-Smoller S, Rohan TE, Ho GY, Anderson GL, Potter JD, Gunter MJ. (2015) A prospective evaluation of endogenous sex hormone levels and colorectal cancer risk in postmenopausal women. J Natl Cancer Inst.107(10). pii: djv210.","DOI":"10.1093\/jnci\/djv210"},{"issue":"9","key":"569_CR132","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1136\/gutjnl-2011-300719","volume":"61","author":"D Limsui","year":"2012","unstructured":"Limsui D, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, Lynch CF, Anderson KE, French AJ, Haile RW, Harnack LJ, Potter JD, Slager SL, Smyrk TC, Thibodeau SN, Cerhan JR, Limburg PJ (2012) Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women. Gut 61(9):1299\u20131305","journal-title":"Gut"},{"issue":"15","key":"569_CR133","doi-asserted-by":"publisher","first-page":"7534","DOI":"10.1158\/0008-5472.CAN-06-4275","volume":"67","author":"PA Newcomb","year":"2007","unstructured":"Newcomb PA, Zheng Y, Chia VM, Morimoto LM, Doria-Rose VP, Templeton A, Thibodeau SN, Potter JD (2007) Estrogen plus progestin use,microsatellite instability, and the risk of colorectal cancer in women. Cancer Res 67(15):7534\u20137539","journal-title":"Cancer Res"},{"issue":"5","key":"569_CR134","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/S0002-9343(99)00063-7","volume":"106","author":"F Grodstein","year":"1999","unstructured":"Grodstein F, Newcomb PA, Stampfer MJ (1999) Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 106(5):574\u2013582","journal-title":"Am J Med"},{"issue":"5 Pt 2","key":"569_CR135","first-page":"880","volume":"93","author":"K Nanda","year":"1999","unstructured":"Nanda K, Bastian LA, Hasselblad V, Simel DL (1999) Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 93(5 Pt 2):880\u2013888","journal-title":"Obstet Gynecol"},{"issue":"2","key":"569_CR136","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/ijc.26026","volume":"130","author":"KJ Lin","year":"2012","unstructured":"Lin KJ, Cheung WY, Lai JY, Giovannucci EL (2012) The effect of estrogen vs.combined estrogen-progestogen therapy on the risk of colorectal cancer. Int J Cancer 130(2):419\u2013430","journal-title":"Int J Cancer"},{"key":"569_CR137","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fonc.2015.00019","volume":"5","author":"F1 Caiazza","year":"2015","unstructured":"Caiazza F1, Ryan EJ1, Doherty G1, Winter DC2, Sheahan K3 (2015) Estrogen receptors and their implications in colorectal carcinogenesis. Front Oncol 5:19","journal-title":"Front Oncol"},{"key":"569_CR138","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1186\/s12885-017-3688-4","volume":"17","author":"PR Stevanato Filho","year":"2017","unstructured":"Stevanato Filho PR, Aguiar S Jr, Begnami MD, Kuasne H, Spencer RM, Nakagawa WT, Bezerra TS, Kupper BC, Takahashi RM, Filho MR, Rogatto SR, Lopes A (2017) Oestrogen receptor beta isoform expression in sporadic colorectal cancer, familial adenomatous polyposis and progressive stages of colorectal cancer. BMC Cancer 17:754","journal-title":"BMC Cancer"},{"key":"569_CR139","doi-asserted-by":"crossref","unstructured":"Stevanato Filho PR, Aguiar J\u00fanior S, Begnami MD, Ferreira FO, Nakagawa WT, Spencer RMSB, Bezerra TS, Boggiss PE, Lopes A. (2018) Estrogen Receptor \u03b2 as a Prognostic Marker of Tumor Progression in Colorectal Cancer with Familial Adenomatous Polyposis and Sporadic Polyps. Pathol Oncol Res (3):533-540.","DOI":"10.1007\/s12253-017-0268-5"},{"key":"569_CR140","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.ejca.2017.06.013","volume":"83","author":"G Topi","year":"2017","unstructured":"Topi G, Ehrnstr\u00f6m R, Jirstr\u00f6m K, Palmquist I, Lydrup ML, Sj\u00f6lander A (2017) Association of the oestrogen receptor beta with hormone status and prognosis in a cohort of female patients with colorectal cancer. Eur J Cancer 83:279\u2013289","journal-title":"Eur J Cancer"},{"issue":"12","key":"569_CR141","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/aje\/kws406","volume":"177","author":"S Karami","year":"2013","unstructured":"Karami S, Daugherty SE, Schonfeld SJ, Park Y, Hollenbeck AR, Grubb RL 3rd, Hofmann JN, Chow WH, Purdue MP (2013) Reproductive factors and kidney cancer risk in 2 US cohort studies, 1993-2010. Am J Epidemiol 177(12):1368\u20131377","journal-title":"Am J Epidemiol"},{"issue":"9","key":"569_CR142","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1002\/ijc.23750","volume":"123","author":"A Zucchetto","year":"2008","unstructured":"Zucchetto A, Talamini R, Dal Maso L, Negri E, Polesel J, Ramazzotti V, Montella M, Canzonieri V, Serraino D, La Vecchia C, Franceschi S (2008) Reproductive, menstrual, and other hormone-related factors and risk of renal cell cancer. Int J Cancer 123(9):2213\u20132216","journal-title":"Int J Cancer"},{"issue":"10","key":"569_CR143","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1093\/aje\/kwp030","volume":"169","author":"JE Lee","year":"2009","unstructured":"Lee JE, Hankinson SE, Cho E (2009) Reproductive factors and risk of renal cell cancer: the Nurses\u2019 Health Study. Am J Epidemiol 169(10):1243\u20131250","journal-title":"Am J Epidemiol"},{"issue":"2","key":"569_CR144","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.maturitas.2007.07.003","volume":"58","author":"JC Molokwu","year":"2007","unstructured":"Molokwu JC, Prizment AE, Folsom AR (2007) Reproductive characteristics and risk of kidney cancer: IowaWomen\u2019s. Maturitas 58(2):156\u2013163","journal-title":"Maturitas"},{"issue":"4","key":"569_CR145","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/BF00146885","volume":"3","author":"M McCredie","year":"1992","unstructured":"McCredie M, Stewart JH (1992) Risk factors for kidney cancer in New South Wales, Australia. II. Urologic disease, hypertension, obesity, and hormonal factors. Cancer Causes Control 3(4):323\u2013331","journal-title":"Cancer Causes Control"},{"issue":"4","key":"569_CR146","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3748\/wjg.v9.i4.665","volume":"9","author":"XH Zhao","year":"2003","unstructured":"Zhao XH, Gu SZ, Liu SX, Pan BR (2003) Expression of estrogen receptor and estrogen receptor messenger RNA in gastric carcinoma tissues. World J Gastroenterol 9(4):665\u2013669","journal-title":"World J Gastroenterol"},{"issue":"5","key":"569_CR147","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/BF00308791","volume":"22","author":"M Matsui","year":"1992","unstructured":"Matsui M, Kojima O, Kawakami S, Uehara Y, Takahashi T (1992) The prognosis of patients with gastric cancer possessing sex hormone receptors. Surg Today 22(5):421\u2013425","journal-title":"Surg Today"},{"issue":"8","key":"569_CR148","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.3748\/wjg.v22.i8.2475","volume":"22","author":"MS Ur Rahman","year":"2016","unstructured":"Ur Rahman MS, Cao J (2016) Estrogen receptors in gastric cancer: Advances and perspectives. World J Gastroenterol 22(8):2475\u20132482","journal-title":"World J Gastroenterol"},{"issue":"25","key":"569_CR149","doi-asserted-by":"publisher","first-page":"40765","DOI":"10.18632\/oncotarget.16582","volume":"8","author":"W Tang","year":"2017","unstructured":"Tang W, Liu R, Yan Y, Pan X, Wang M, Han X, Ren H, Zhang Z (2017) Expression of estrogen receptors and androgen receptor and their clinical significance in gastric cancer. Oncotarget 8(25):40765\u201340777","journal-title":"Oncotarget"},{"issue":"13","key":"569_CR150","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1245\/s10434-016-5448-0","volume":"23","author":"HW Kim","year":"2016","unstructured":"Kim HW, Kim JH, Lim BJ, Kim H, Kim H, Park JJ, Youn YH, Park H, Noh SH, Kim JW, Choi SH (2016) Sex Disparity in Gastric Cancer: Female Sex is a Poor Prognostic Factor for Advanced Gastric Cancer. Ann Surg Oncol 23(13):4344\u20134351","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"569_CR151","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1002\/ijc.30588","volume":"140","author":"N Brusselaers","year":"2017","unstructured":"Brusselaers N, Maret-Ouda J, Konings P, El-Serag HB, Lagergren J (2017) Menopausal hormone therapy and the risk of esophageal and gastric cancer. Int J Cancer 140(7):1693\u20131699","journal-title":"Int J Cancer"},{"issue":"5","key":"569_CR152","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/ijc.2910440515","volume":"44","author":"HO1 Adami","year":"1989","unstructured":"Adami HO1, Persson I, Hoover R, Schairer C, Bergkvist L (1989) Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 44(5):833\u2013839","journal-title":"Int J Cancer"},{"key":"569_CR153","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1479-5876-12-93","volume":"12","author":"L Shi","year":"2014","unstructured":"Shi L, Feng Y, Lin H, Ma R, Cai X (2014) Role of estrogen in hepatocellular carcinoma: is inflammation the key? J Transl Med 12:93","journal-title":"J Transl Med"},{"key":"569_CR154","doi-asserted-by":"publisher","first-page":"854530","DOI":"10.1155\/2015\/854530","volume":"2015","author":"M Montella","year":"2015","unstructured":"Montella M, D\u2019Arena G, Crispo A, Capunzo M, Nocerino F, Grimaldi M, Barbieri A, D\u2019Ursi AM, Tecce MF, Amore A, Galdiero M, Ciliberto G, Giudice A (2015) Role of Sex Hormones in the Development and Progression of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Int J Endocrinol 2015:854530","journal-title":"Int J Endocrinol"},{"issue":"11","key":"569_CR155","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/j.cgh.2017.05.036","volume":"15","author":"MM Hassan","year":"2017","unstructured":"Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, Kaseb AO (2017) Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 15(11):1791\u20131799","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"569_CR156","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0302-2838(02)00038-6","volume":"41","author":"A Basakci","year":"2002","unstructured":"Basakci A, Kirkali Z, Tuzel E, Yorukoglu K, Mungan MU, Sade M (2002) Prognostic significance of estrogen receptor expression in superficial transitional cell carcinoma of the urinary bladder. Eur Urol 41(3):342\u2013345","journal-title":"Eur Urol"},{"issue":"3","key":"569_CR157","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/ijc.11083","volume":"105","author":"E Fernandez","year":"2003","unstructured":"Fernandez E, Gallus S, Bosetti C, Franceschi S, Negri E, La Vecchia C (2003) Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer 105(3):408\u2013412","journal-title":"Int J Cancer"},{"issue":"2","key":"569_CR158","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3233\/BLC-160052","volume":"2","author":"G Godoy","year":"2016","unstructured":"Godoy G, Gakis G, Smith CL, Fahmy O (2016) Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression. Bladder Cancer 2(2):127\u2013137","journal-title":"Bladder Cancer"},{"issue":"5","key":"569_CR159","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/S0022-5347(05)66370-7","volume":"165","author":"D Dellagrammaticas","year":"2001","unstructured":"Dellagrammaticas D, Bryden AA, Collins GN (2001) Regression of metastatic transitional cell carcinoma in response to tamoxifen. J Urol 165(5):1631","journal-title":"J Urol"},{"issue":"1B","key":"569_CR160","first-page":"711","volume":"21","author":"CH Hsu","year":"2001","unstructured":"Hsu CH, Chen J, Wu CY, Cheng AL, Pu YS (2001) Combination chemotherapy of cisplatin, methotrexate, vinblastine, , and high-dose tamoxifen for transitional cell carcinoma. Anticancer Res 21(1B):711\u2013715","journal-title":"Anticancer Res"},{"issue":"19","key":"569_CR161","doi-asserted-by":"publisher","first-page":"27325","DOI":"10.18632\/oncotarget.8756","volume":"7","author":"Z Shang","year":"2016","unstructured":"Shang Z, Li Y, Hsu I, Zhang M, Tian J, Wen S, Han R, Messing EM, Chang C, Niu Y, Yeh S (2016) Targeting estrogen\/estrogen receptor alpha enhances Bacillus Calmette-Gu\u00e9rin efficacy in bladder cancer. Oncotarget 7(19):27325\u201327335","journal-title":"Oncotarget"},{"key":"569_CR162","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3389\/fendo.2017.00111","volume":"8","author":"M Moleti","year":"2017","unstructured":"Moleti M, Sturniolo G, Di Mauro M, Russo M, Vermiglio F (2017) Female Reproductive Factors and Differentiated Thyroid Cancer. Front Endocrinol (Lausanne) 8:111","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"569_CR163","first-page":"425","volume":"5","author":"MR Galanti","year":"1996","unstructured":"Galanti MR, Hansson L, Lund E, Bergstr\u00f6m R, Grimelius L, Stalsberg H, Carlsen E, Baron JA, Persson I, Ekbom A (1996) Reproductive history and cigarette smoking as risk factors for thyroid cancer in women: a population-based case-control study. Cancer Epidemiol Biomark Prev 5(6):425\u2013431","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"569_CR164","unstructured":"Mack WJ, Preston-Martin S, Bernstein L, Qian D, Xiang M. (1999) Reproductive and hormonal risk factors for thyroid cancer in Los Angeles county females. Cancer Epidemiol Biomarkers Prev. 8(11):991-997."},{"issue":"8","key":"569_CR165","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/oxfordjournals.aje.a010276","volume":"151","author":"MA Rossing","year":"2000","unstructured":"Rossing MA, Voigt LF, Wicklund KG, Daling JR (2000) Reproductive factors and risk of papillary thyroid cancer in women. Am J Epidemiol 151(8):765\u2013772","journal-title":"Am J Epidemiol"},{"issue":"1","key":"569_CR166","first-page":"51","volume":"11","author":"LC Sakoda","year":"2002","unstructured":"Sakoda LC, Horn-Ross PL (2002) Reproductive and menstrual history and papillary thyroid cancer risk: the San Francisco bay area thyroid cancer study. Cancer Epidemiol Biomark Prev 11(1):51\u201357","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"1","key":"569_CR167","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/ijc.1573","volume":"97","author":"A Memon","year":"2002","unstructured":"Memon A, Darif M, Al-Saleh K, Suresh A (2002) Epidemiology of reproductive and hormonal factors in thyroid cancer: evidence from a case-control study in the Middle East. Int J Cancer 97(1):82\u201389","journal-title":"Int J Cancer"},{"issue":"11","key":"569_CR168","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/aje\/kwi136","volume":"161","author":"T Truong","year":"2005","unstructured":"Truong T, Orsi L, Dubourdieu D, Rougier Y, H\u00e9mon D, Gu\u00e9nel P (2005) Role of goiter and of menstrual and reproductive factors in thyroid cancer: a population- based case-control study in New Caledonia (South Pacific), a very high incidence area. Am J Epidemiol 161(11):1056\u20131065","journal-title":"Am J Epidemiol"},{"issue":"4","key":"569_CR169","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000452488","volume":"5","author":"G Sturniolo","year":"2016","unstructured":"Sturniolo G, Zafon C, Moleti M, Castellv\u00ed J, Vermiglio F, Mesac J (2016) Immunohistochemical Expression of Estrogen Receptor-\u03b1 and Progesterone Receptor in Patients with Papillary Thyroid Cancer. Eur Thyroid J 5(4):224\u2013230","journal-title":"Eur Thyroid J"},{"issue":"12","key":"569_CR170","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1245\/s10434-017-5780-z","volume":"24","author":"JW Yi","year":"2017","unstructured":"Yi JW, Kim SJ, Kim JK, Seong CY, Yu HW, Chai YJ, Choi JY, Lee KE (2017) Upregulation of the ESR1 Gene and ESR Ratio (ESR1\/ESR2) is Associated with a Worse Prognosis in Papillary Thyroid Carcinoma: The Impact of the Estrogen Receptor \u03b1\/\u03b2 Expression on Clinical Outcomes in Papillary Thyroid Carcinoma Patients. Ann Surg Oncol 24(12):3754\u20133762","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 1","key":"569_CR171","first-page":"383","volume":"54","author":"H Jastrzebska","year":"2001","unstructured":"Jastrzebska H, Gietka-Czernel M, Zgliczy\u0144ski S (2001) Hormonal replacement therapy in women after surgery for thyroid cancer treated with suppressive doses of L-thyroxine. Wiad Lek 54(Suppl 1):383\u2013388","journal-title":"Wiad Lek"},{"issue":"7","key":"569_CR172","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1097\/MD.0000000000000177","volume":"94","author":"B Tang","year":"2015","unstructured":"Tang B, Lv J, Li Y, Yuan S, Wang Z, He S (2015) Relationship between female hormonal and menstrual factors and pancreatic cancer: a meta-analysis of observational studies. Medicine (Baltimore) 94(7):e177","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"569_CR173","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288(3):321\u2013333","journal-title":"JAMA"},{"issue":"9003","key":"569_CR174","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S0140-6736(96)90075-6","volume":"347","author":"YT Schouw van der","year":"1996","unstructured":"van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD (1996) Age at menopause as a risk factor for cardiovascular mortality. Lancet 347(9003):714\u2013718","journal-title":"Lancet"},{"issue":"2","key":"569_CR175","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3109\/13697137.2013.771520","volume":"16","author":"TJ Villiers de","year":"2013","unstructured":"de Villiers TJ, Gass ML, Haines CJ, Hall JE, Lobo RA, Pierroz DD, Rees M (2013) Global Consensus Statement on Menopausal Hormone Therapy. Climacteric 16(2):203\u2013204","journal-title":"Climacteric"}],"container-title":["Pathology &amp; Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-018-00569-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-018-00569-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-018-00569-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T10:06:23Z","timestamp":1585821983000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-018-00569-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,8]]},"references-count":175,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["569"],"URL":"https:\/\/doi.org\/10.1007\/s12253-018-00569-x","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"value":"1219-4956","type":"print"},{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,8]]},"assertion":[{"value":"23 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}